GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leadersà insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.
Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth
By GBI Research | Pharmaceuticals and Healthcare | Jan 2019 | Page 140
Global Womens Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth The womens health therapy area covers medical disorders....
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry
By GBI Research | Pharmaceuticals and Healthcare | Jan 2019 | Page 180
Global Rheumatic Disorders Drugs Market to 2024 - Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry The rheumatic disorder therapy area is....
Gastrointestinal Diseases Drug Development Pipeline Review, 2018
By GBI Research | Pharmaceuticals and Healthcare | Dec 2018 | Page 98
Gastrointestinal Diseases Drug Development Pipeline Review, 2018 This report provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under....
Renal Diseases Drug Development Pipeline Review, 2018
By GBI Research | Pharmaceuticals and Healthcare | Dec 2018 | Page 154
Renal Diseases Drug Development Pipeline Review, 2018 This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under....
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market
By GBI Research | Pharmaceuticals and Healthcare | Dec 2018 | Page 112
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market Non-alcoholic steatohepatitis (NASH) is the severe....